A significant proportion of clinically at-risk patients with certain immunocompromised or immunosuppressed conditions mount a low or undetectable immune response after two doses of the same COVID-19 vaccine
Professor Pam Kearns, Director of the Institute of Cancer and Genomic Sciences, writes an opinion piece on how COVID-19 has replaced cancer as 'the big C'.
A new and less invasive treatment developed by researchers is safer than standard major surgery for early-stage rectal cancer, giving patients a better quality of life with fewer life-altering side effects.